PremiumRatingsAltimmune’s Pemvidutide: A Promising Best-in-Class Therapy with Broad Potential and Strong Buy Rating Biotech Alert: Searches spiking for these stocks today Altimmune call volume above normal and directionally bullish PremiumRatingsAltimmune’s Pemvidutide: Promising Future with IMPACT Trial and Market Expansion Altimmune’s Earnings Call: Progress Amid Challenges Altimmune Reports Progress in Clinical Trials and Financials PremiumThe FlyAltimmune reports Q4 EPS (33c), consensus (34c) Altimmune Expands Board Amid Late-Stage Drug Development Altimmune appoints Teri Lawver, Jerry Durso to board 
